Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis

J Am Acad Dermatol. 2021 Jul;85(1):265-267. doi: 10.1016/j.jaad.2020.09.046. Epub 2020 Sep 19.

Authors

Justine Cheng¹, Lai Jiang¹, Nicole C Morrow¹, Armin Avdic¹, Janet A Fairley², Jennifer J Ling¹, Mark A Greiner³

Affiliations

¹ Department of Ophthalmology and Visual Sciences, University of Iowa Carver College of Medicine, Iowa City, Iowa.
² Department of Dermatology, University of Iowa Carver College of Medicine, Iowa City, Iowa.
³ Department of Ophthalmology and Visual Sciences, University of Iowa Carver College of Medicine, Iowa City, Iowa. Electronic address: mark-greiner@uiowa.edu.

PMID: 32956738
DOI: 10.1016/j.jaad.2020.09.046

No abstract available

Publication types

Letter

MeSH terms

Algorithms
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Dermatitis, Atopic / drug therapy*
Humans
Keratoconjunctivitis / chemically induced*
Keratoconjunctivitis / diagnosis

Substances

Antibodies, Monoclonal, Humanized
dupilumab